Cargando…

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice

BACKGROUND: Cerebrospinal fluid (CSF) biomarkers are increasingly being used for diagnosis of Alzheimer’s disease (AD). OBJECTIVE: We investigated the influence of CSF intralaboratory and interlaboratory variability on diagnostic CSF-based AD classification of subjects and identified causes of this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vos, Stephanie J. B., Visser, Pieter Jelle, Verhey, Frans, Aalten, Pauline, Knol, Dirk, Ramakers, Inez, Scheltens, Philip, Rikkert, Marcel G. M. Olde., Verbeek, Marcel M., Teunissen, Charlotte E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069102/ https://www.ncbi.nlm.nih.gov/pubmed/24959687 http://dx.doi.org/10.1371/journal.pone.0100784

Ejemplares similares

Diagnostic and economic evaluation of new biomarkers for Alzheimer’s disease: the research protocol of a prospective cohort study
por: Handels, Ron LH, et al.
Publicado: (2012)

Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease
por: Geijselaers, Stefan L.C., et al.
Publicado: (2017)

Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
por: Bos, Isabelle, et al.
Publicado: (2017)

Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
por: Bos, Isabelle, et al.
Publicado: (2018)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports
por: Slats, Diane, et al.
Publicado: (2010)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
por: Tijms, Betty Marije, et al.
Publicado: (2021)

A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands
por: Liao, Weiqi, et al.
Publicado: (2016)

Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer’s Disease
por: van de Beek, Marleen, et al.
Publicado: (2019)

Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia
por: Banning, Leonie C. P., et al.
Publicado: (2019)

A comparison of two approaches for modeling dementia progression in a changing patient context
por: Wubben, Nina, et al.
Publicado: (2022)

The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results
por: Aalten, Pauline, et al.
Publicado: (2014)

Cognitive and functional progression of dementia in two longitudinal studies
por: Wang, Yuwei, et al.
Publicado: (2019)

Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
por: Vromen, Eleonora M, et al.
Publicado: (2022)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Development of memory clinics in the Netherlands over the last 20 years
por: Gruters, Angélique A.A., et al.
Publicado: (2019)

Memory enhancing drugs and Alzheimer’s Disease: Enhancing the self or preventing the loss of it?
por: Dekkers, Wim, et al.
Publicado: (2007)

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
por: Bertens, Daniela, et al.
Publicado: (2017)

Tear biomarkers for Alzheimer’s disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study
por: van de Sande, Nienke, et al.
Publicado: (2023)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Clinical characteristics of patients with suspected Alzheimer’s disease within a CSF Aß-ratio grey zone
por: Yosypyshyn, Dariia, et al.
Publicado: (2023)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
por: Konijnenberg, Elles, et al.
Publicado: (2020)

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial
por: Abdullah, Laila, et al.
Publicado: (2020)

Pre-trained MRI-based Alzheimer's disease classification models to classify memory clinic patients
por: de Vos, Frank, et al.
Publicado: (2020)

The Role of Information and Communication Technologies in Clinical Trials with Patients with Alzheimer’s Disease and Related Disorders
por: König, Alexandra, et al.
Publicado: (2015)

Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration
por: Gijs, Marlies, et al.
Publicado: (2021)

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics
por: Tijms, Betty M, et al.
Publicado: (2020)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
por: Duits, Flora H., et al.
Publicado: (2021)

Discovery of novel CSF biomarkers to predict progression in dementia using machine learning
por: Gogishvili, Dea, et al.
Publicado: (2023)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Automatic speech analysis for the assessment of patients with predementia and Alzheimer's disease
por: König, Alexandra, et al.
Publicado: (2015)

A Scoping Review of Communicating Neuropsychological Test Results to Patients and Family Members
por: Gruters, Angélique AA, et al.
Publicado: (2021)

Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation
por: Neumann, Alexander, et al.
Publicado: (2022)

New CSF biomarkers on the block
por: Teunissen, Charlotte E, et al.
Publicado: (2016)

Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
por: Neumann, Alexander, et al.
Publicado: (2023)

Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study
por: Rombach, Ines, et al.
Publicado: (2020)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ii1j37jego4kk3461d3l06ogcn